Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NR3C2 | P08235 | 1/20 | 0.36 |
| ▸ | NR1H2 | P55055 | 2/20 | 0.35 |
| ▸ | NTRK1 | P04629 | 2/20 | 0.35 |
| ▸ | NTRK2 | Q16620 | 2/20 | 0.35 |
| ▸ | TP53 | P04637 | 1/20 | 0.34 |
| ▸ | MAPT | P10636 | 1/20 | 0.34 |
| ▸ | GNRHR | P30968 | 1/20 | 0.34 |
| ▸ | HTT | P42858 | 1/20 | 0.34 |
| ▸ | PTGDR2 | Q9Y5Y4 | 1/20 | 0.34 |
| ▸ | HCRTR1 | O43613 | 1/20 | 0.34 |
| ▸ | HCRTR2 | O43614 | 1/20 | 0.34 |
| ▸ | CA12 | O43570 | 1/20 | 0.33 |
| ▸ | CA1 | P00915 | 1/20 | 0.33 |
| ▸ | CA2 | P00918 | 1/20 | 0.33 |
| ▸ | CA3 | P07451 | 1/20 | 0.33 |
| ▸ | CA4 | P22748 | 1/20 | 0.33 |
| ▸ | CA6 | P23280 | 1/20 | 0.33 |
| ▸ | CA5A | P35218 | 1/20 | 0.33 |
| ▸ | CA7 | P43166 | 1/20 | 0.33 |
| ▸ | CA9 | Q16790 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3957947 | 0.92 | NR1H2 (0.37) | NR3C2NR1H2TP53MAPTGNRHR | |
| SCHEMBL6714823 | 0.89 | MEN1 (0.38) | NR3C2TP53PTGDR2MEN1KMT2A | |
| SCHEMBL6717372 | 0.89 | TRPV1 (0.38) | P2RX7 | |
| SCHEMBL1623250 | 0.89 | PTGER4 (0.41) | NR1H2NTRK1NTRK2MAPTGNRHR | |
| SCHEMBL6714655 | 0.87 | PTGER4 (0.38) | NR1H2NTRK1NTRK2GNRHRPTGER4 | |
| SCHEMBL3949473 | 0.87 | PTGER2 (0.37) | NR1H2MAPTPTGER4MEN1KMT2A | |
| SCHEMBL1624850 | 0.87 | PTGER4 (0.35) | NTRK1NTRK2TP53GNRHRHCRTR1 | |
| SCHEMBL6713167 | 0.87 | PTGER4 (0.41) | NR1H2NTRK1NTRK2TP53MAPT | |
| SCHEMBL1625127 | 0.86 | NR3C1 (0.34) | NR1H2TP53MAPTPTGDR2PTGER4 | |
| SCHEMBL6710720 | 0.86 | PTGER4 (0.39) | NR1H2NTRK1NTRK2MAPTGNRHR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 17 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1326864-B1 | ARYL OR HETEROARYL FUSED IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS | PFIZER PHARMA (JP) | 2006-03-15 | — | — | EP | claimed |
| US-20040181059-A1 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | ASKAT INC. (JP) | 2004-09-16 | — | — | US | claimed |
| US-20020107273-A1 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | ASKAT INC. (JP) | 2002-08-08 | — | — | US | claimed |
| EP-1666480-B1 | Aryl or Heteroaryl Fused Imidazole Compounds as intermediates for Anti-Inflammatory And Analgesic Agents. | RAQUALIA PHARMA INC (JP) | 2014-10-01 | — | — | EP | disclosed |
| WO-2011102149-A1 | USE OF EP4 RECEPTOR ANTAGONISTS IN THE TREATMENT OF IL-23 MEDIATED DISEASES | RAQUALIA PHARMA INC. (JP) | 2011-08-25 | — | — | WO | disclosed |
| US-7928119-B2 | Use of EP4 receptor ligands in the treatment of IL-6 involved diseases | PFIZER INC. (US) | 2011-04-19 | — | — | US | disclosed |
| US-7479564-B2 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | RAQUALIA PHARMA INC. (JP) | 2009-01-20 | — | — | US | disclosed |
| US-20070155732-A1 | Aryl or Heteroaryl Fused Imidazole Compounds as Anti-Inflammatory and Analgesic Agents | PFIZER INC. | 2007-07-05 | — | — | US | disclosed |
| US-7148234-B2 | Use of EP4 receptor ligands in the treatment of IL-6 involved diseases | PFIZER INC. (US) | 2006-12-12 | — | — | US | disclosed |
| US-7141580-B2 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | PFIZER INC. (US) | 2006-11-28 | — | — | US | disclosed |
| EP-1666480-A1 | Aryl or Heteroaryl Fused Imidazole Compounds as intermediates for Anti-Inflammatory And Analgesic Agents. | PFIZER PHARMACEUTICALS INC. (JP) | 2006-06-07 | — | — | EP | disclosed |
| EP-1326864-B1 | ARYL OR HETEROARYL FUSED IMIDAZOLE COMPOUNDS AS ANTI-INFLAMMATORY AND ANALGESIC AGENTS | PFIZER PHARMA (JP) | 2006-03-15 | — | — | EP | disclosed |
| US-20040181059-A1 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | ASKAT INC. (JP) | 2004-09-16 | — | — | US | disclosed |
| US-6710054-B2 | CONTAINING SULFONYLAMINOCARBONYL GROUPS; PROSTAGLANDIN INHIBITORS | PFIZER INC | 2004-03-23 | — | — | US | disclosed |
| US-20030236260-A1 | Use of EP4 receptor ligands in the treatment of IL-6 involved diseases | SHIMOJO MASATO | 2003-12-25 | — | — | US | disclosed |
| US-20020107273-A1 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | ASKAT INC. (JP) | 2002-08-08 | — | — | US | disclosed |
| US-20020077329-A1 | EP4 receptor inhibitors to treat rheumatoid arthritis | PFIZER PHARMACEUTICALS INC. (JP) | 2002-06-20 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20020107273-A1 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | PTGS1, PTGS2, OPRM1 | NR3C2 463/4885NR1H2 213/4885NTRK1 3557/4885 |
| US-20030236260-A1 | Use of EP4 receptor ligands in the treatment of IL-6 involved diseases | PTGER4, PTGER1, IL6 | NR3C2 207/4885NR1H2 310/4885NTRK1 2177/4885 |
| US-20040181059-A1 | Aryl or heteroaryl fused imidazole compounds as anti-inflammatory and analgesic agents | PTGS1, PTGS2, OPRM1 | NR3C2 469/4885NR1H2 208/4885NTRK1 3530/4885 |
| US-20070155732-A1 | Aryl or Heteroaryl Fused Imidazole Compounds as Anti-Inflammatory and Analgesic Agents | PTGS1, PTGS2, PTGES | NR3C2 357/4885NR1H2 300/4885NTRK1 3135/4885 |
| US-20020077329-A1 | EP4 receptor inhibitors to treat rheumatoid arthritis | PTGER4, PTGER1, PTGER2 | NR3C2 250/4885NR1H2 252/4885NTRK1 1252/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.